Sharp Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Sharp Therapeutics.
Sharp Therapeutics Overview
About Sharp Therapeutics
Sharp Therapeutics Corp is a preclinical-stage drug discovery company developing therapeutics for genetic diseases. It has developed the patent-protected Disco discovery platform consisting of the CoreX biology, AlloChem chemistry, and Mine computational technologies to discover drugs that selectively activate the protein that’s been altered by gene mutation. The company has targeted its discovery engine (Disco) to three hereditary disorders with high unmet need, which include Gaucher’s Disease, Familial Frontotemporal Dementia, and Niemann Pick Type-C. Its drug development pipeline consists of the following candidates: SEL-148, 721, SEL-148, 742, and SEL-147, 124. Geographically, the company's business operations are carried out in the United States of America.
Founded
2021
HQ
Employees
N/A
Website
Financials (FY)
EV
$20M
Valuation Multiples
Start free trial
Sharp Therapeutics Financials
Sharp Therapeutics reported last fiscal year revenue of - and negative EBITDA of ($6M).
In the same fiscal year, Sharp Therapeutics generated ($6M) in EBITDA losses and had net loss of ($6M).
Sharp Therapeutics P&L
In the most recent fiscal year, Sharp Therapeutics reported revenue of - and EBITDA of ($6M).
Sharp Therapeutics is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.
Financial data powered by Morningstar, Inc.
Sharp Therapeutics Stock Performance
Sharp Therapeutics has current market cap of $20M, and enterprise value of $20M.
Sharp Therapeutics' stock price is $0.65.
Sharp Therapeutics has an EPS (earnings per share) of $-0.21.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $20M | $20M | -0.2% | - | - | - | $-0.21 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSharp Therapeutics Valuation Multiples
Sharp Therapeutics trades at (3.4x) EV/EBITDA.
Sharp Therapeutics Financial Valuation Multiples
As of August 14, 2026, Sharp Therapeutics has market cap of $20M and EV of $20M.
Sharp Therapeutics has a P/E ratio of (3.2x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Sharp Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Sharp Therapeutics Margins & Growth Rates
Sharp Therapeutics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Sharp Therapeutics Competitors
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
This data is available for Pro users. Sign up to see all Sharp Therapeutics competitors and their valuation data. Start Free Trial | ||||||
Sharp Therapeutics VC Funding History
Before going public, Sharp Therapeutics raised $4M in total equity funding, across 4 rounds.
Sharp Therapeutics Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Sharp Therapeutics
| When was Sharp Therapeutics founded? | Sharp Therapeutics was founded in 2021. |
| Where is Sharp Therapeutics headquartered? | Sharp Therapeutics is headquartered in United States. |
| Is Sharp Therapeutics publicly listed? | Yes, Sharp Therapeutics is a public company listed on Toronto Stock Exchange. |
| What is the stock symbol of Sharp Therapeutics? | Sharp Therapeutics trades under SHRX ticker. |
| When did Sharp Therapeutics go public? | Sharp Therapeutics went public in 2024. |
| Who are competitors of Sharp Therapeutics? | Sharp Therapeutics main competitors include |
| What is the current market cap of Sharp Therapeutics? | Sharp Therapeutics' current market cap is $20M. |
| Is Sharp Therapeutics profitable? | No, Sharp Therapeutics is not profitable. |
| How many companies Sharp Therapeutics has acquired to date? | Sharp Therapeutics hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Sharp Therapeutics has invested to date? | Sharp Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly). |
Lists including Sharp Therapeutics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.